Genentech, a member of the Roche, announced that Kadcyla significantly extended the time people with advanced HER2-positive breast cancer lived without their disease worsening compared to people who received a treatment of their physician’s choice in an open-label Phase III study called TH3RESA. The data showed the risk of disease worsening or death was reduced by 47% for people who received Kadcyla. Data for overall survival, the other co-primary endpoint, are not yet mature. No new safety signals were observed with Kadcyla. The study enrolled people with advanced HER2-positive breast cancer who had progressed despite prior treatment with at least two HER2-targeted medicines. It randomized people to receive either treatment with Kadcyla or a treatment of their physician’s choice. Eighty percent of people treated with physician’s choice received a regimen containing Herceptin.